

Supplementary Material

Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience

Aurora Zanghi¹, Diana Ferraro², Graziella Callari³, Paola Valentino⁴, Franco Granella⁵, Francesco Patti⁶, Giacomo Lus⁷, Simona Bonavita⁸, Maria Claudia Moretti¹, Carlo Avolio¹ and Emanuele D'Amico^{1,*}

¹Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; ²University of Modena and Reggio Emilia, Modena, Emilia-Ronagna, Italy; ³IRCSS G.Giglio, Cefalù, Italy; ⁴Azienda Ospedaliera Universitaria "Mater Domini", Catanzaro, Italy; ⁵Unit of Neurosciences, Department of Medicine and Surgery, University of Parma, Parma, Italy and Multiple Sclerosis Centre, Department of General Medicine, Parma University Hospital, Parma, Italy; ⁶Department "G.F. Ingrassia"; MS center University of Catania, Catania, Italy; ⁷Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy; ⁸Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Università della Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138 Naples, Italy

STROBE Checklist

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract		
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found		
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported		
Objectives	3	State specific objectives, including any prespecified hypotheses		
Methods				
Study design	4	Present key elements of study design early in the paper		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		
Participants	6	a) Cohort study —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up		
		b) Case-control study —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		c) Cross-sectional study —Give the eligibility criteria, and the sources and methods of selection of participants		
		d) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed		
		e) Case-control study —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable		
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group		
Bias	9	Describe any efforts to address potential sources of bias		

STROBE Checklist

Study size	10	Explain how the study size was arrived at		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding		
		(b) Describe any methods used to examine subgroups and interactions		
		(c) Explain how missing data were addressed		
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy		
		(e) Describe any sensitivity analyses		
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed		
		(b) Give reasons for non-participation at each stage		
		(c) Consider use of a flow diagram		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders		
		(b) Indicate number of participants with missing data for each variable of interest		
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)		
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time		
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure		
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included		
		(b) Report category boundaries when continuous variables were categorized		

STROBE Checklist

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		
Discussion				
Key results	18	Summarise key results with reference to study objectives		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		
Generalisability	21	Discuss the generalisability (external validity) of the study results		
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		

***Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.**